[go: up one dir, main page]

AR083847A1 - Variantes de fc (fragmento constante) silenciosas de los anticuerpos anti-cd40 - Google Patents

Variantes de fc (fragmento constante) silenciosas de los anticuerpos anti-cd40

Info

Publication number
AR083847A1
AR083847A1 ARP110104221A ARP110104221A AR083847A1 AR 083847 A1 AR083847 A1 AR 083847A1 AR P110104221 A ARP110104221 A AR P110104221A AR P110104221 A ARP110104221 A AR P110104221A AR 083847 A1 AR083847 A1 AR 083847A1
Authority
AR
Argentina
Prior art keywords
antibodies
silencers
variants
antibody
polypeptide
Prior art date
Application number
ARP110104221A
Other languages
English (en)
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=44925566&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=AR083847(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of AR083847A1 publication Critical patent/AR083847A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2878—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70578—NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2866—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2875—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF/TNF superfamily, e.g. CD70, CD95L, CD153, CD154
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/71—Decreased effector function due to an Fc-modification

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Genetics & Genomics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biomedical Technology (AREA)
  • Zoology (AREA)
  • Microbiology (AREA)
  • Wood Science & Technology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Transplantation (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Rheumatology (AREA)
  • Cell Biology (AREA)
  • Endocrinology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Pain & Pain Management (AREA)
  • Physical Education & Sports Medicine (AREA)

Abstract

Se presentan además, composiciones y métodos de uso de estos anticuerpos, para el tratamiento de trastornos patológicos, tales como trastornos autoinmunes e inflamatorios, y/o para prevenir o reducir el riesgo de rechazo de injerto en el trasplante.Reivindicación 1: Un anticuerpo aislado o una proteína que comprende una porción de enlace de antígeno de un anticuerpo dirigido contra un polipéptido de CD40 objetivo (SEQ ID Nº 28), caracterizado porque este anticuerpo o esta proteína: a) se enlaza al polipéptido de CD40 con una KD de 10 nM o menos, y b) comprende una región Fc de lgG silenciosa.
ARP110104221A 2010-11-15 2011-11-11 Variantes de fc (fragmento constante) silenciosas de los anticuerpos anti-cd40 AR083847A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US41356710P 2010-11-15 2010-11-15

Publications (1)

Publication Number Publication Date
AR083847A1 true AR083847A1 (es) 2013-03-27

Family

ID=44925566

Family Applications (2)

Application Number Title Priority Date Filing Date
ARP110104221A AR083847A1 (es) 2010-11-15 2011-11-11 Variantes de fc (fragmento constante) silenciosas de los anticuerpos anti-cd40
ARP210102014A AR122999A2 (es) 2010-11-15 2021-07-16 Variantes de fc silenciosas de los anticuerpos anti-cd40

Family Applications After (1)

Application Number Title Priority Date Filing Date
ARP210102014A AR122999A2 (es) 2010-11-15 2021-07-16 Variantes de fc silenciosas de los anticuerpos anti-cd40

Country Status (39)

Country Link
US (8) US8828396B2 (es)
EP (4) EP4023676A1 (es)
JP (1) JP5782132B2 (es)
KR (1) KR101632775B1 (es)
CN (2) CN105949314B (es)
AR (2) AR083847A1 (es)
AU (1) AU2011331288B2 (es)
BR (1) BR112013011644B1 (es)
CA (1) CA2815921C (es)
CL (1) CL2013001124A1 (es)
CO (1) CO6801629A2 (es)
CR (1) CR20130222A (es)
CU (1) CU24057B1 (es)
CY (2) CY1119097T1 (es)
DK (2) DK2640749T3 (es)
EA (1) EA026133B1 (es)
ES (2) ES2633817T3 (es)
GT (1) GT201300128A (es)
HR (2) HRP20220413T1 (es)
HU (2) HUE058015T2 (es)
IL (1) IL225719A (es)
JO (1) JO3266B1 (es)
LT (2) LT3502138T (es)
MA (1) MA34654B1 (es)
MX (1) MX336633B (es)
MY (1) MY159316A (es)
NZ (1) NZ609549A (es)
PE (1) PE20140979A1 (es)
PH (1) PH12013500973A1 (es)
PL (2) PL3502138T3 (es)
PT (2) PT2640749T (es)
RS (2) RS63094B1 (es)
SG (1) SG189928A1 (es)
SI (2) SI2640749T1 (es)
TW (2) TWI608016B (es)
UA (1) UA112417C2 (es)
UY (2) UY39292A (es)
WO (1) WO2012065950A1 (es)
ZA (1) ZA201302532B (es)

Families Citing this family (92)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009095478A1 (en) 2008-01-31 2009-08-06 INSERM (Institut National de la Santé et de la Recherche Médicale) Antibodies against human cd39 and use thereof for inhibiting t regulatory cells activity
AR083847A1 (es) 2010-11-15 2013-03-27 Novartis Ag Variantes de fc (fragmento constante) silenciosas de los anticuerpos anti-cd40
US9125893B2 (en) * 2011-02-17 2015-09-08 Kyowa Hakko Kirin Co., Ltd. Highly concentrated anti-CD40 antibody pharmaceutical preparation
CA3122934A1 (en) 2011-03-11 2012-09-20 Beth Israel Deaconess Medical Center, Inc. Fusion protein comprising a fragment of cd40 and method of producing same
CN106977604A (zh) 2011-04-21 2017-07-25 百时美施贵宝公司 拮抗cd40之抗体多肽
ES2709654T3 (es) 2011-04-29 2019-04-17 Apexigen Inc Anticuerpos anti-CD40 y métodos de uso
SMT202000091T1 (it) 2011-10-13 2020-05-08 Bristol Myers Squibb Co Polipeptidi anticorpali che antagonizzano cd40l
US20140004131A1 (en) * 2012-05-04 2014-01-02 Novartis Ag Antibody formulation
AU2013337903B2 (en) 2012-10-30 2018-08-16 Apexigen, Inc. Anti-CD40 antibodies and methods of use
JP6333943B2 (ja) 2013-03-15 2018-05-30 ノバルティス アーゲー 抗体薬物コンジュゲート
US10435475B2 (en) 2014-03-07 2019-10-08 Bristol-Myers Squibb Company Method of using antibody polypeptides that antagonize CD40 to treat IBD
US10786578B2 (en) 2014-08-05 2020-09-29 Novartis Ag CKIT antibody drug conjugates
BR112017001588A2 (pt) 2014-08-12 2017-11-21 Novartis Ag conjugados de anticorpo/fármaco anti-cdh6
PT3204417T (pt) 2014-10-10 2020-10-08 Innate Pharma Bloqueio de cd73
EP3229586A4 (en) 2014-12-10 2018-10-24 Regents of the University of Minnesota Genetically modified cells, tissues, and organs for treating disease
GB201501613D0 (en) * 2015-01-30 2015-03-18 Ucb Biopharma Sprl Treatment of autoimmune disorders with CD154 antibodies
EP3081942A1 (en) * 2015-04-17 2016-10-19 Roche Diagniostics GmbH Pressure transmission liquid for cellular analyzer, cellular analyzer and method for analyzing a liquid cellular sample
CA2987051A1 (en) 2015-05-29 2016-12-08 Abbvie Inc. Anti-cd40 antibodies and uses thereof
WO2017040932A1 (en) 2015-09-04 2017-03-09 Primatope Therapeutics Inc. Humanized anti-cd40 antibodies and uses thereof
WO2017044424A1 (en) * 2015-09-08 2017-03-16 Theripion, Inc. Apoa-1 fusion polypeptides and related compositions and methods
US9862760B2 (en) 2015-09-16 2018-01-09 Novartis Ag Polyomavirus neutralizing antibodies
CN109069622A (zh) 2015-09-30 2018-12-21 詹森生物科技公司 特异性结合人cd40的拮抗性抗体和使用方法
US11130817B2 (en) 2015-10-12 2021-09-28 Innate Pharma CD73 blocking agents
AU2017204936B2 (en) 2016-02-10 2019-06-27 Novartis Ag Use of inhibitors of the activity or function of PI3K for the treatment of primary Sjogren's Syndrome
JP7270379B2 (ja) 2016-03-08 2023-05-10 イナート・ファルマ・ソシエテ・アノニム Ｓｉｇｌｅｃ中和抗体
WO2017157948A1 (en) 2016-03-14 2017-09-21 Innate Pharma Anti-cd39 antibodies
JP7461741B2 (ja) 2016-06-20 2024-04-04 カイマブ・リミテッド 抗ｐｄ－ｌ１およびｉｌ－２サイトカイン
WO2018065552A1 (en) 2016-10-06 2018-04-12 Innate Pharma Anti-cd39 antibodies
WO2018083080A2 (en) 2016-11-04 2018-05-11 Innate Pharma Nkp46 ligand
EP3551034A1 (en) 2016-12-07 2019-10-16 Progenity, Inc. Gastrointestinal tract detection methods, devices and systems
JP7246321B2 (ja) 2017-01-24 2023-03-27 インネイト ファーマ ＮＫｐ４６結合物質
WO2018141959A1 (en) 2017-02-06 2018-08-09 Innate Pharma Immunomodulatory antibody drug conjugates binding to a human mica polypeptide
EP3596124A1 (en) 2017-03-16 2020-01-22 Innate Pharma Compositions and methods for treating cancer
CN110582264B (zh) * 2017-03-26 2022-11-11 V·R·斯塔福德 眼睑皮肤状况的处理方法
EP3600416B1 (en) 2017-03-30 2023-06-07 Biora Therapeutics, Inc. Treatment of a disease of the gastrointestinal tract with an immune modulatory agent released using an ingestible device
WO2018185618A1 (en) 2017-04-03 2018-10-11 Novartis Ag Anti-cdh6 antibody drug conjugates and anti-gitr antibody combinations and methods of treatment
JP7257335B2 (ja) 2017-05-25 2023-04-13 ブリストル－マイヤーズ スクイブ カンパニー アンタゴニスト性ｃｄ４０モノクローナル抗体およびその使用
WO2018217988A1 (en) * 2017-05-25 2018-11-29 Bristol-Myers Squibb Company MODIFIED IgG1 Fc DOMAINS AND ANTI-CD40 DOMAIN ANTIBODY FUSIONS THEREWITH
CN110506058A (zh) * 2017-06-02 2019-11-26 豪夫迈·罗氏有限公司 免疫激动剂的施用路径
JP7293188B2 (ja) 2017-07-10 2023-06-19 イナート・ファルマ・ソシエテ・アノニム Ｓｉｇｌｅｃ－９中和抗体
CA3066571A1 (en) 2017-07-10 2019-01-17 Innate Pharma Combination therapy using antibody to human siglec-9 and antibody to human nkg2a for treating cancer
KR102716961B1 (ko) 2017-09-19 2024-10-11 엠에이비 디스커버리 게엠베하 효능작용 cd40 항체
MX2020004411A (es) * 2017-11-03 2020-08-06 Novartis Ag Anticuerpos anti-cd40 para usarse en el tratamiento del sindrome de sjogren.
CN111417651B (zh) 2017-12-01 2023-09-29 诺华股份有限公司 多瘤病毒中和抗体
KR20200143718A (ko) * 2018-04-13 2020-12-24 노파르티스 아게 이식편 거부반응 예방에 사용하기 위한 항-cd40 항체
IT201800004853A1 (it) 2018-04-24 2019-10-24 Metodi per trattare il cancro
WO2019229699A1 (en) 2018-05-31 2019-12-05 Novartis Ag Hepatitis b antibodies
CN112638375A (zh) 2018-06-15 2021-04-09 旗舰创业创新五公司 通过后细胞信号传导因子的调节来增加免疫活性
KR20210023983A (ko) 2018-06-18 2021-03-04 이나뜨 파르마 암을 치료하기 위한 조성물 및 방법
US20230041197A1 (en) 2018-06-20 2023-02-09 Progenity, Inc. Treatment of a disease of the gastrointestinal tract with an immunomodulator
WO2019246317A1 (en) 2018-06-20 2019-12-26 Progenity, Inc. Treatment of a disease or condition in a tissue originating from the endoderm
WO2020053742A2 (en) 2018-09-10 2020-03-19 Novartis Ag Anti-hla-hbv peptide antibodies
AR117091A1 (es) 2018-11-19 2021-07-07 Bristol Myers Squibb Co Anticuerpos monoclonales antagonistas contra cd40 y sus usos
US20220249814A1 (en) 2018-11-19 2022-08-11 Progenity, Inc. Methods and devices for treating a disease with biotherapeutics
WO2020128863A1 (en) 2018-12-19 2020-06-25 Novartis Ag Anti-tnf-alpha antibodies
WO2020136145A2 (en) 2018-12-26 2020-07-02 Innate Pharma Leucocyte immunoglobulin-like receptor neutralizing antibodies
CN113271964A (zh) * 2019-01-11 2021-08-17 诺华股份有限公司 化脓性汗腺炎治疗中使用的抗cd40抗体
BR112021021224A2 (pt) 2019-04-23 2021-12-21 Innate Pharma Anticorpos ou fragmentos de anticorpos, composição farmacêutica, kit, ácido nucleico ou conjunto de ácidos nucleicos, célula hospedeira recombinante e método para o tratamento ou a prevenção de uma doença em um paciente em necessidade do mesmo
WO2020227159A2 (en) 2019-05-03 2020-11-12 Flagship Pioneering Innovations V, Inc. Methods of modulating immune activity
KR20220007086A (ko) 2019-05-08 2022-01-18 노파르티스 아게 T1dm 및 췌도염의 치료에 사용하기 위한 항-cd40 항체
KR20230031981A (ko) 2019-05-14 2023-03-07 프로벤션 바이오, 인코포레이티드 제1형 당뇨병을 예방하기 위한 방법 및 조성물
CR20210607A (es) 2019-06-12 2022-01-21 Novartis Ag Anticuerpos de receptor de péptido natriurético 1 y métodos de uso
FI3993876T3 (fi) * 2019-07-01 2024-11-28 Tonix Pharma Ltd Cd154-vasta-aineita ja niiden käyttötarkoituksia
WO2021048595A1 (en) * 2019-09-11 2021-03-18 Novartis Ag A method for preventing human virus associated disorders in patients
KR20220064983A (ko) 2019-09-18 2022-05-19 노파르티스 아게 Nkg2d 융합 단백질 및 이의 용도
CN115666704A (zh) 2019-12-13 2023-01-31 比奥拉治疗股份有限公司 用于将治疗剂递送至胃肠道的可摄取装置
US20230114107A1 (en) 2019-12-17 2023-04-13 Flagship Pioneering Innovations V, Inc. Combination anti-cancer therapies with inducers of iron-dependent cellular disassembly
CN115397394A (zh) * 2020-01-31 2022-11-25 赛诺菲 抗体的肺部递送
CN115175695A (zh) 2020-02-27 2022-10-11 诺华股份有限公司 制备表达嵌合抗原受体的细胞的方法
KR20230092863A (ko) 2020-06-11 2023-06-26 프로벤션 바이오, 인코포레이티드 제1형 당뇨병을 예방하기 위한 방법 및 조성물
EP4172323A1 (en) 2020-06-29 2023-05-03 Flagship Pioneering Innovations V, Inc. Viruses engineered to promote thanotransmission and their use in treating cancer
JP2023537115A (ja) 2020-08-13 2023-08-30 イナート・ファルマ・ソシエテ・アノニム 抗ｃｄ７３抗体を使用する癌処置方法
MX2023002107A (es) 2020-08-21 2023-03-15 Novartis Ag Composiciones y metodos para la generacion in vivo de celulas que expresan car.
CN116234909A (zh) * 2020-08-21 2023-06-06 上海药明生物技术有限公司 Cd40激动剂抗体和使用方法
WO2022097065A2 (en) 2020-11-06 2022-05-12 Novartis Ag ANTIBODY Fc VARIANTS
WO2022130182A1 (en) 2020-12-14 2022-06-23 Novartis Ag Reversal binding agents for anti-natriuretic peptide receptor 1 (npr1) antibodies and uses thereof
KR20230165276A (ko) 2021-03-31 2023-12-05 플래그쉽 파이어니어링 이노베이션스 브이, 인크. 타노트랜스미션 폴리펩티드 및 암의 치료에서의 이의 용도
TW202309095A (zh) * 2021-06-28 2023-03-01 大陸商江蘇恆瑞醫藥股份有限公司 抗cd40抗體、其抗原結合片段及醫藥用途
KR20240026507A (ko) 2021-06-29 2024-02-28 플래그쉽 파이어니어링 이노베이션스 브이, 인크. 타노트랜스미션을 촉진시키도록 엔지니어링된 면역 세포 및 이의 용도
AR126838A1 (es) 2021-08-20 2023-11-22 Novartis Ag Métodos para preparar células que expresan receptores de antígeno quiméricos
US20250002527A1 (en) 2021-08-26 2025-01-02 Duality Biologics (Suzhou) Co., Ltd. Steroid compound and conjugate thereof
US20230203176A1 (en) * 2021-09-17 2023-06-29 Novartis Ag Methods For Prevention Of Graft Rejection In Xenotransplantation
AU2022350419A1 (en) 2021-09-24 2024-05-02 Chia Tai Tianqing Pharmaceutical Group Co., Ltd. Anti-cd40 antibody and use thereof
CN118139886A (zh) 2021-10-01 2024-06-04 Mab发现股份有限公司 作为免疫刺激剂的激动性cd40抗体
EP4499221A1 (en) 2022-03-30 2025-02-05 Novartis AG Methods of treating disorders using anti-natriuretic peptide receptor 1 (npr1) antibodies
TW202423983A (zh) 2022-09-15 2024-06-16 瑞士商諾華公司 使用嵌合抗原受體療法的自體免疫性障礙的治療
US20240174732A1 (en) 2022-10-05 2024-05-30 Flagship Pioneering Innovations V, Inc. Nucleic acid molecules encoding trif and additional polypeptides and their use in treating cancer
WO2024107752A2 (en) 2022-11-15 2024-05-23 Onestone Therapeutics Llc Compositions and methods for immunomodulatory bifunctional fusion molecules
WO2024140917A1 (zh) * 2022-12-28 2024-07-04 上海盛迪医药有限公司 抗cd40抗体药物偶联物、其制备方法及其医药用途
US20240269251A1 (en) 2023-01-09 2024-08-15 Flagship Pioneering Innovations V, Inc. Genetic switches and their use in treating cancer
WO2024259206A1 (en) 2023-06-16 2024-12-19 Regeneron Pharmaceuticals, Inc. Cd40 x cd40 bispecific antigen-binding molecules and uses thereof
WO2025023895A1 (en) * 2023-07-26 2025-01-30 Db Biotech, A.S. Antibody against complement component c4d

Family Cites Families (73)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4766A (en) 1846-09-19 Stbaw-cutter
US106A (en) 1915-08-24 Specipication
US4179337A (en) 1973-07-20 1979-12-18 Davis Frank F Non-immunogenic polypeptides
US5179017A (en) 1980-02-25 1993-01-12 The Trustees Of Columbia University In The City Of New York Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
US4399216A (en) 1980-02-25 1983-08-16 The Trustees Of Columbia University Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
US4634665A (en) 1980-02-25 1987-01-06 The Trustees Of Columbia University In The City Of New York Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
JPS5896026A (ja) 1981-10-30 1983-06-07 Nippon Chemiphar Co Ltd 新規ウロキナ−ゼ誘導体およびその製造法ならびにそれを含有する血栓溶解剤
DE3380726D1 (en) 1982-06-24 1989-11-23 Japan Chem Res Long-acting composition
US4766106A (en) 1985-06-26 1988-08-23 Cetus Corporation Solubilization of proteins for pharmaceutical compositions using polymer conjugation
GB8601597D0 (en) 1986-01-23 1986-02-26 Wilson R H Nucleotide sequences
US5260203A (en) 1986-09-02 1993-11-09 Enzon, Inc. Single polypeptide chain binding molecules
US4881175A (en) 1986-09-02 1989-11-14 Genex Corporation Computer based system and method for determining and displaying possible chemical structures for converting double- or multiple-chain polypeptides to single-chain polypeptides
CA1294215C (en) 1986-10-27 1992-01-14 Ze'ev Shaked Pharmaceutical compositions of recombinant beta-interferon and formulation processes
CA1292686C (en) 1986-10-27 1991-12-03 Ze'ev Shaked Pharmaceutical compositions of recombinant interleukin-2 and formulation process
US5013653A (en) 1987-03-20 1991-05-07 Creative Biomolecules, Inc. Product and process for introduction of a hinge region into a fusion protein to facilitate cleavage
US5091513A (en) 1987-05-21 1992-02-25 Creative Biomolecules, Inc. Biosynthetic antibody binding sites
US5132405A (en) 1987-05-21 1992-07-21 Creative Biomolecules, Inc. Biosynthetic antibody binding sites
US5258498A (en) 1987-05-21 1993-11-02 Creative Biomolecules, Inc. Polypeptide linkers for production of biosynthetic proteins
AU612370B2 (en) 1987-05-21 1991-07-11 Micromet Ag Targeted multifunctional proteins
GB8717430D0 (en) 1987-07-23 1987-08-26 Celltech Ltd Recombinant dna product
GB8809129D0 (en) 1988-04-18 1988-05-18 Celltech Ltd Recombinant dna methods vectors and host cells
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
US5874082A (en) 1992-07-09 1999-02-23 Chiron Corporation Humanized anti-CD40 monoclonal antibodies and fragments capable of blocking B cell proliferation
US5397703A (en) 1992-07-09 1995-03-14 Cetus Oncology Corporation Method for generation of antibodies to cell surface molecules
AU686230B2 (en) 1993-10-01 1998-02-05 Immunex Corporation Antibodies to CD40
NZ278740A (en) 1993-12-23 1998-05-27 Immunex Corp Treating disease characterised by neoplastic cells expressing cd40 using a cd40 binding protein
ES2204944T3 (es) 1994-03-03 2004-05-01 Alexion Pharmaceuticals, Inc. Genes y proteinas de fusion inhibidores del complemento terminal.
GB9425060D0 (en) 1994-12-13 1995-02-08 Univ Birmingham Carcinoma treatment
NZ500539A (en) 1995-07-27 2001-11-30 Genentech Inc An antibody that binds HER2 receptor in a composition for treating endometrial, lung, colon or bladder cancer
IL133220A0 (en) 1997-06-13 2001-03-19 Genentech Inc Stabilized antibody formulation
IL133305A0 (en) 1997-06-20 2001-04-30 Biogen Inc Use of a cd40:cd154 binding interruptor for treating protein inhibitor syndrome
PT1017413E (pt) 1997-09-23 2003-02-28 Rentschler Biotech Gmbh Formulacoes liquidas de interferao (beta)
US6051228A (en) 1998-02-19 2000-04-18 Bristol-Myers Squibb Co. Antibodies against human CD40
US20020006901A1 (en) 1999-02-05 2002-01-17 Aldo T. Iacono Use of aerosolized cyclosporine for prevention and treatment of pulmonary disease
WO2002004021A1 (en) 2000-07-12 2002-01-17 Idec Pharmaceuticals Corporation Treatment of b cell malignancies using combination of b cell depleting antibody and immune modulating antibody related applications
AU1590201A (en) 1999-11-09 2001-06-06 Chiron Corporation Compositions and methods for treating autoimmune diseases and transplant rejections
US7063845B2 (en) 2000-04-28 2006-06-20 Gemini Science, Inc. Human anti-CD40 antibodies
WO2001083755A2 (en) 2000-04-28 2001-11-08 La Jolla Institute For Allergy And Immunology Human anti-cd40 antibodies and methods of making and using same
US20030059427A1 (en) 2000-04-28 2003-03-27 Force Walker R. Isolation and characterization of highly active anti-CD40 antibody
JP2004508420A (ja) 2000-09-18 2004-03-18 アイデック　ファーマスーティカルズ　コーポレイション Ｂ細胞枯渇抗体／免疫調節性抗体の組合せを用いて自己免疫疾患を治療するための併用療法
WO2002028480A2 (en) 2000-10-02 2002-04-11 Chiron Corporation Methods of therapy for b-cell malignancies
CA2436180C (en) 2001-01-31 2011-11-08 Idec Pharmaceutical Corporation Immunoregulatory antibodies and uses thereof
AU2002250352C1 (en) 2001-04-02 2009-04-30 Genentech, Inc. Combination therapy
DK1391464T3 (da) 2001-04-27 2008-01-14 Kirin Pharma Kk Anti-CD40 monoklonalt antistof
WO2003029296A1 (en) 2001-10-02 2003-04-10 Chiron Corporation Human anti-cd40 antibodies
AR039067A1 (es) * 2001-11-09 2005-02-09 Pfizer Prod Inc Anticuerpos para cd40
CA2466931A1 (en) 2001-11-26 2003-06-05 Chiron Corporation Antagonist anti-cd40 monoclonal antibody therapy for multiple sclerosis treatment
US20080199471A1 (en) * 2002-03-01 2008-08-21 Bernett Matthew J Optimized cd40 antibodies and methods of using the same
AU2003217912A1 (en) * 2002-03-01 2003-09-16 Xencor Antibody optimization
DK3417875T3 (da) 2003-02-10 2020-08-31 Biogen Ma Inc Immunglobulinformulering og fremgangsmåde til fremstilling deraf
PT1684869E (pt) 2003-11-04 2011-09-16 Novartis Vaccines & Diagnostic Métodos de terapêutica para cancros relacionados com células b
KR20070028295A (ko) 2003-11-04 2007-03-12 노바티스 백신즈 앤드 다이아그노스틱스 인코포레이티드 만성 임파세포성 백혈병의 치료에 사용되는 길항제항-ｃｄ４０ 항체의 용도
PL1680141T3 (pl) 2003-11-04 2011-04-29 Novartis Vaccines & Diagnostics Inc Sposoby leczenia guzów litych wykazujących ekspresję antygenu powierzchniowego CD40
PT1682180E (pt) 2003-11-04 2010-02-10 Novartis Vaccines & Diagnostic Anticorpos monoclonais antagonistas anti-cd40 e métodos para a sua utilização
US8277810B2 (en) 2003-11-04 2012-10-02 Novartis Vaccines & Diagnostics, Inc. Antagonist anti-CD40 antibodies
WO2005044855A2 (en) 2003-11-04 2005-05-19 Chiron Corporation Use of antagonist anti-cd40 monoclonal antibodies for treatment of multiple myeloma
BRPI0417266B8 (pt) * 2003-12-25 2021-05-25 Kyowa Hakko Kirin Co Ltd anticorpo monoclonal, seu uso e composição farmacêutica
CA2564296A1 (en) * 2004-04-27 2006-07-13 Novartis Vaccines And Diagnostics, Inc. Antagonist anti-cd40 monoclonal antibodies and methods for their use
US20080057070A1 (en) * 2004-11-04 2008-03-06 Chiron Corporation Antagonist Anti-Cd40 Monoclonal Antibodies and Methods for Their Use
PT1889065E (pt) 2005-05-18 2013-09-27 Novartis Ag Métodos para o diagnóstico e tratamento de doenças tendo uma componente autoimune e/ou inflamatória
ES2428089T3 (es) 2005-11-01 2013-11-05 Novartis Ag Usos de anticuerpos anti-cd40
AR057253A1 (es) * 2005-12-16 2007-11-21 Genentech Inc Anticuerpos anti-ox40l y metodos que los utilizan
AR060487A1 (es) 2006-04-21 2008-06-18 Xoma Technology Ltd Composiciones farmaceuticas de antagonistas del anticuerpo anti- cd40
EP1854810A1 (en) 2006-05-09 2007-11-14 PanGenetics B.V. Deimmunized antagonistic anti-human CD40 monoclonal antibody from the ch5D12 antibody
US7803377B2 (en) * 2006-06-06 2010-09-28 Genentech, Inc. Anti-DLL4 antibodies and methods using same
WO2008122007A1 (en) * 2007-04-02 2008-10-09 Genentech, Inc. Biological markers predictive of rheumatoid arthritis response to b-cell antagonists
TW201446265A (zh) * 2007-04-02 2014-12-16 Genentech Inc 克羅梭（ｋｌｏｔｈｏ）ｂｅｔａ調節劑之用途
AU2008260498B2 (en) * 2007-05-30 2012-11-29 Xencor, Inc. Methods and compositions for inhibiting CD32b expressing cells
PT2376535T (pt) * 2008-12-09 2017-06-23 Hoffmann La Roche Anticorpos anti-pd-l1 e a sua utilização para a melhoria do funcionamento das células t
NZ595825A (en) * 2009-04-20 2012-10-26 Kyowa Hakko Kirin Co Ltd Antibody containing igg2 having amino acid mutation introduced therein
AR083847A1 (es) 2010-11-15 2013-03-27 Novartis Ag Variantes de fc (fragmento constante) silenciosas de los anticuerpos anti-cd40
US20140004131A1 (en) 2012-05-04 2014-01-02 Novartis Ag Antibody formulation
US9668768B2 (en) 2013-03-15 2017-06-06 Synaptive Medical (Barbados) Inc. Intelligent positioning system and methods therefore

Also Published As

Publication number Publication date
JP5782132B2 (ja) 2015-09-24
IL225719A (en) 2017-09-28
UY33728A (es) 2012-06-29
ZA201302532B (en) 2014-09-25
PL3502138T3 (pl) 2022-05-02
EP3502138B9 (en) 2022-03-09
PT3502138T (pt) 2022-04-06
DK2640749T3 (en) 2017-07-31
KR20130080856A (ko) 2013-07-15
UY39292A (es) 2021-07-30
RS56153B1 (sr) 2017-11-30
SG189928A1 (en) 2013-06-28
US9688768B2 (en) 2017-06-27
ES2911460T3 (es) 2022-05-19
EP4023676A1 (en) 2022-07-06
CR20130222A (es) 2013-06-28
EP3502138B1 (en) 2022-01-19
BR112013011644A2 (pt) 2016-08-02
US20200087409A1 (en) 2020-03-19
US9221913B2 (en) 2015-12-29
TW201305208A (zh) 2013-02-01
HRP20220413T1 (hr) 2022-05-27
CA2815921C (en) 2021-07-06
BR112013011644B1 (pt) 2022-02-22
US20140341898A1 (en) 2014-11-20
JP2014500720A (ja) 2014-01-16
PH12013500973A1 (en) 2013-07-08
AR122999A2 (es) 2022-10-19
IL225719A0 (en) 2013-06-27
SI2640749T1 (sl) 2017-07-31
JO3266B1 (ar) 2018-09-16
TWI531581B (zh) 2016-05-01
TW201623335A (zh) 2016-07-01
GT201300128A (es) 2015-06-02
CY1125252T1 (el) 2024-12-13
AU2011331288A1 (en) 2013-05-02
PE20140979A1 (es) 2014-08-09
AU2011331288B2 (en) 2014-09-11
EP2640749A1 (en) 2013-09-25
WO2012065950A1 (en) 2012-05-24
US20220204635A1 (en) 2022-06-30
CN103209996B (zh) 2016-07-20
CN103209996A (zh) 2013-07-17
US20240228640A9 (en) 2024-07-11
SI3502138T1 (sl) 2022-05-31
HUE058015T2 (hu) 2022-06-28
EA201390725A1 (ru) 2013-09-30
CA2815921A1 (en) 2012-05-24
US20120121585A1 (en) 2012-05-17
US11124578B2 (en) 2021-09-21
EP3222636A1 (en) 2017-09-27
NZ609549A (en) 2015-05-29
CL2013001124A1 (es) 2014-07-04
CO6801629A2 (es) 2013-11-29
US20180118843A1 (en) 2018-05-03
PT2640749T (pt) 2017-07-25
HUE034203T2 (en) 2018-01-29
CU20130071A7 (es) 2013-09-27
US9828433B2 (en) 2017-11-28
CY1119097T1 (el) 2018-01-10
CN105949314A (zh) 2016-09-21
US8828396B2 (en) 2014-09-09
KR101632775B1 (ko) 2016-06-22
ES2633817T3 (es) 2017-09-25
EA026133B1 (ru) 2017-03-31
HRP20171084T1 (hr) 2017-10-06
US10323096B2 (en) 2019-06-18
LT2640749T (lt) 2017-07-10
CN105949314B (zh) 2021-04-09
US20240132606A1 (en) 2024-04-25
CU24057B1 (es) 2014-12-26
US20160152721A1 (en) 2016-06-02
LT3502138T (lt) 2022-04-11
DK3502138T3 (da) 2022-04-19
MX336633B (es) 2016-01-26
PL2640749T3 (pl) 2017-09-29
MX2013005477A (es) 2013-06-12
TWI608016B (zh) 2017-12-11
MY159316A (en) 2016-12-30
EP2640749B1 (en) 2017-04-19
MA34654B1 (fr) 2013-11-02
US20170267772A1 (en) 2017-09-21
RS63094B1 (sr) 2022-04-29
UA112417C2 (uk) 2016-09-12
EP3502138A1 (en) 2019-06-26

Similar Documents

Publication Publication Date Title
AR083847A1 (es) Variantes de fc (fragmento constante) silenciosas de los anticuerpos anti-cd40
AR091069A1 (es) Proteinas de union a antigeno dirigidas contra el receptor st2
AR079336A1 (es) Antagonistas de la pro-proteina convertasa-subtilisina/quexina tipo 9 (pcsk9)
AR083747A1 (es) Anticuerpos anti-il-23
ES2584956T3 (es) Anticuerpos anti-CD40 y usos de los mismos
MX2021007006A (es) Anticuerpo anti-calicreina-2 humanizado.
ES2621874T3 (es) Anticuerpos para MUC16 y métodos de uso de los mismos
EA201101593A1 (ru) КОМПОЗИЦИИ И СПОСОБЫ, ПРЕДНАЗНАЧЕННЫЕ ДЛЯ НАПРАВЛЕННОГО ВОЗДЕЙСТВИЯ АНТИТЕЛ НА БЕЛОК С3b СИСТЕМЫ КОМПЛЕМЕНТА
PE20091196A1 (es) Anticuerpos contra el vegf completamente humano, composiciones y metodos
NO20082905L (no) Anti-IL-17 antistoff
AR082518A1 (es) Anticuerpos contra il-18r1 y usos de los mismos
AR068508A1 (es) Anticuerpo capaz de enlazar linfopoyetina estromal timica
AR060017A1 (es) Composiciones y metodos de uso para anticuerpos de dickkopf -1
NZ601271A (en) Cd127 binding proteins
PE20110225A1 (es) Composiciones y metodos para anticuerpos que se dirigen a la proteina de complemento c5
PE20181076A1 (es) Nuevos moduladores y metodos para su uso
EA201400568A1 (ru) Альбуминсвязывающие антитела и их связывающие фрагменты
EA201491214A1 (ru) Композиции и способы применения антител, нацеленных на фактор p
PH12014500167A1 (en) Tnf-alpha antigen-binding proteins with increased fcrn binding
EA201592006A1 (ru) Новые биспецифические связывающие молекулы с противоопухолевой активностью
CY1118420T1 (el) Αντι-ιδιοτυπικο αντισωμα εναντι ενος αντισωματος εναντι του βητα αμυλοειδους πεπτιδιου
NZ601615A (en) Antibodies that bind to lysyl oxidase-like 2 (loxl2) and methods of use therefor
ES2639026T3 (es) Anticuerpos totalmente humanos específicos para CADM1
EA201490677A1 (ru) Связывающие антиген cd27l белки
MX2014003689A (es) Anticuerpos contra tl1a y sus usos.

Legal Events

Date Code Title Description
FG Grant, registration